Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain
- 24 December 2004
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 24 (1) , 23-30
- https://doi.org/10.1007/s10096-004-1267-5
Abstract
This study, included in the prospective survey of candidaemia in Europe supported by the European Confederation of Medical Mycology, presents the epidemiological and antifungal susceptibility results of 290 cases of candidaemia (80 in children andida albicans (46/36.2), C. parapsilosis (21.9/50), C. tropicalis (12.8/3.75), and C. glabrata (10.1/5). As initial therapy, fluconazole was preferred in adults (54%) and liposomal amphotericin B in children (58%). The 30-day mortality rate was 40.6%, and the species most frequently associated with a fatal outcome was C. krusei (60%). The rates of susceptibility to antifungal agents were as follows: amphotericin B, 91%; flucytosine, 99%; fluconazole, 93.6%; itraconazole, 87.4%; and voriconazole, 92%. These results provide baseline data for future epidemiological and susceptibility studies and for evaluating the impact of new antifungal agents on the distribution of species and the mortality rates associated with candidaemia in Spain.Keywords
This publication has 49 references indexed in Scilit:
- Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance StudyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2002
- Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for DeathEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Antifungal Susceptibility Testing: Practical Aspects and Current ChallengesClinical Microbiology Reviews, 2001
- Prevalence and Antifungal Susceptibility of 442 Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, CanadaJournal of Clinical Microbiology, 2001
- Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998Antimicrobial Agents and Chemotherapy, 2000
- Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes☆Diagnostic Microbiology and Infectious Disease, 2000
- Antifungal resistance in non- albicans Candida speciesDrug Resistance Updates, 1999
- Candidemia in a Tertiary Care Hospital: Epidemiology, Risk Factors, and Predictors of MortalityClinical Infectious Diseases, 1992
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of internal medicine (1960), 1988